You are here

Home » Content

EFFECTS OF ATENOLOL AND NEBIVOLOL ALONE AND COMBINATION WITH GLIPIZIDE ON GLUCOSE LEVELS IN NORMAL AND STZ INDUCED DIABETIC RATS

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Drugs are used in the prevention and treatment of symptoms and diseases but the drug-drug interactions are one of the major problems in multi-drug therapy. Beta blockers are commonly used in the treatment of hypertension in diabetic patient. Literature showed that risk of retinopathy and cardiovascular disease are more in diabetic hypertensive patients, which may cause morbidity and mortality. Therefore present study was undertaken to understand the effects of atenolol and nebivolol alone and combination with glipizide in normal and diabetic rats. The study was conducted on healthy albino andstreptozotocin induced diabetic rats. Diabetes was induced by single i.p. injection of STZ (60mg/kg) administration. The hypoglycemic effects of atenolol, nebivolol and glipizidealone and in combination were tested. Results showed that atenolol and glipizide did not have any significant effect on glucose levels on alone administration. Though repeated administration of atenolol followed by glipizide enhances hypoglycemic effect of glipizide up to one hour followed reduced hypoglycemic effect of glipizidethroughout the study period in normal animals but potentiated the hypoglycemic effect of glipizide on diabetic animals. However, nebivolol does not alter antidiabetic activity of glipizide. Hence study suggested that the dose and/or frequency of atenolol administration have to be readjusted accordingly when glipizide and atenolol need to be used concomitantly. Nebivolol is safe drug in patients having diabetes and hypertension than atenolol.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon ijprbs_299.pdf
  • 5
533-542
  • English

REFERENCES

References: 

1. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33).
Lancet. 1998;352:837-853 [Erratum. Lancet. 1999;354:602].
3. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:1011¬1053.
4. Bell DSH. B-andrenergic blocking agents with diabetes - friend and foe. EndocrPract 1999; 5: 51-53.
5. Sawicki PT, Siebenhofer A. Betablockers and Diabetes Mellitus. J Clin Basic Cardiol
2001; 14: 17-20.
6. Bell DS. Advantages of a third generation beta blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93: 49-52.
7. Xhonneux R, Wouters L, Reneman RS, et al. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. Eur J Pharmacol
1990;181:261.
8. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J ClinPharmacol 1994;38:199.
9. Bennett P.N., M.J. Brown; Clinical Pharmacology, Churchill Livingstone, New York, 2003, 9, 683-688.
10. Devis, S.N. In: L.L. Brunton, K.L. Parker, (Eds.), Goodman & Gilman's ThePharmacological Basis Of Therapeutics,
11. (McGraw-Hill, New York, 2006).
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 39. BMJ 1998; 317: 713¬20.
12. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-25.
13. Kaplan NM Treatment of Co-existing diabetes and hypertension.Current Cardiology Reports (2001) 3: 498-503.
14. Gurwitz JH, Goldberg J, Chen Z, Gore JM, Alpert JS. ^-blocker therapy in acute myocardial infarction: Evidence for underutilization in the elderly. Am J Med
1992; 93: 605-10.

Thank you for copying data from http://www.arastirmax.com